![]() |
[Home] [Databases] [World Law] [Multidatabase Search] [Help] [Feedback] | |
England and Wales Court of Appeal (Civil Division) Decisions |
||
You are here: BAILII >> Databases >> England and Wales Court of Appeal (Civil Division) Decisions >> Regen Lab SA v Estar Medical Ltd & Ors [2020] EWCA Civ 451 (24 March 2020) URL: http://www.bailii.org/ew/cases/EWCA/Civ/2020/451.html Cite as: [2020] EWCA Civ 451 |
[New search] [Printable PDF version] [Help]
ON APPEAL FROM THE HIGH COURT OF JUSTICE
BUSINESS AND PROPERTY COURTS OF ENGLAND AND WALES
HHJ Hacon
Strand, London, WC2A 2LL |
||
B e f o r e :
____________________
REGEN LAB SA |
Appellant |
|
- and - |
||
(1) ESTAR MEDICAL LIMITED (2) ESTAR TECHNOLOGIES LIMITED (3) MEDIRA LIMITED (4) LAVENDER MEDICAL LIMITED (5) ANTOINE TURZI |
Respondents |
____________________
Gareth Morgan (solicitor, CMS Cameron MacKenna Nabarro Olswang LLP) for the Respondents
Telephone hearing date: 19 March 2020
____________________
Crown Copyright ©
Lord Justice Floyd :
i) An application dated 17 October but sealed on 21 October 2019 by Estar seeking an order that, unless Regen pay the sums owed to them pursuant to orders for costs made in the court below, the appeal should be struck out. By the same application Estar seeks an order that, in the event the appeal is to proceed, Regen is to provide it with security for costs by paying the sum of £267,421 into court, and, in default, the appeal is to be struck out ("Estar's strike out and security application").
ii) An application by Regen dated 28 February but sealed on 5 March 2020 for a stay of the appeal to this court pending (i) the final outcome of the EPO appeal and/or (ii) the final outcome of criminal proceedings in Switzerland against Estar. By the same application notice Regen seeks "postponement of the appeal" to this court, by which I understand it to mean an adjournment ("Regen's stay and adjournment application").
iii) A further application by Regen of the same date contains seven heads of relief including (i) a stay of execution in respect of all costs awarded to Estar; (ii) an order denying the relief sought on Estar's applications; (iii) relief from sanctions for failing to pay any costs to Estar; (iv) a refund to Regen for its costs incurred in "the present application"; (v) security for Regen's costs of the appeal and/or cross-appeal in the sum of £270,000, paid into court; (vi) an order striking out the cross-appeal unless Estar pays the costs of this application within 14 days; (vii) if the sum for costs is so paid, then security for costs ("Regen's combined application").
"Given that approach by [Regen] there does not seem to me anything even approaching a good reason to extend the time for payment of the £225,000, whether until the outcome of the appeal or for any other period."
"Q. If RegenLab wanted to, would it be able to pay that 225,000 pounds?
A. Of course.
…
Q. Is RegenLab seeking finance to enable itself to pay the 225,000 pound [sic] ordered by the U.K. court?
A. No."
"Despite the withdrawal of the current ITC (see above), Regen will continue enforcement of its patent rights in Europe and the USA. Regen is seeking damages for at least 10 million USD for patent infringement by Estar since 2008 and reimbursement of all legal costs incurred. It appears that the only activity of Estar is to commercialise copycats of Regen's products. It would therefore be desirable for the PRP [platelet rich plasma] industry that Estar disappears from the market."
"In view of the aforementioned, it was and is still impossible for Regen to meet the deadlines as set forth in the schedule. Regen will not be able to prepare bundles for tomorrow, March 4 2020 and to prepare appropriately for the April 1, 2020 deadline. Rights of Regen in order to appropriately prepare for the Appeal have been restricted in a substantial manner. As mentioned in Regen's application, if the Appeal is not stayed (as in France and German[y]) then Regen requests a delay, a new schedule for the Appeal and postponement of the Appeal."
Note 1 It is true that at one stage it was being asserted that Regen had temporary financial difficulties, and that payment of the March and July costs orders would stifle its appeal, but those assertions were never supported by evidence, and more recently Regen has been saying that it is in good financial shape. [Back]